×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| Concord Drugs Limited | NA | NA | NA | NA | 66.0 | 153.0 |
| Aspira Pathlab & Diagnostics L | NA | NA | NA | NA | 64.8 | 25.3 |
| Jeevan Scientific Technology L | NA | NA | NA | NA | 63.4 | 1,268 |
Concord Drugs Limited, with Security Code 538965, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.5 | 11.5 | 8.8 | 7.4 | 12.6 | 14.5 | 6.4 | 11.8 | 10.8 | 0.8 |
| Expenses | 12.1 | 10.8 | 7.4 | 5.9 | 12.1 | 14.3 | 5.6 | 11.0 | 9.5 | 7.0 |
| Operating Profit | 1.4 | 0.7 | 1.4 | 1.5 | 0.6 | 0.2 | 0.7 | 0.8 | 1.3 | -6.2 |
| OPM % | 10.67% | 6.42% | 15.91% | 20.7% | 4.44% | 1.29% | 11.51% | 6.7% | 12.2% | -780.35% |
| Other Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 |
| Depreciation | 0.4 | 0.3 | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.4 | 0.4 |
| Profit before tax | 0.6 | 0.0 | 0.6 | 0.8 | -0.3 | -0.6 | 0.0 | 0.1 | 0.5 | -7.1 |
| Tax % | -26.3% | 305.9% | -22.7% | -30.9% | -6.3% | -38.9% | -55.6% | -27% | -57.4% | 0% |
| Net Profit | 0.5 | 0.1 | 0.5 | 0.5 | -0.2 | -0.4 | 0.0 | 0.1 | 0.2 | -7.2 |
| EPS in Rs | 0.52 | 0.07 | 0.52 | 0.56 | -0.24 | -0.35 | 0.01 | 0.05 | 0.22 | 0 |
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.3 | 9.0 | 7.5 | 12.8 | 15.6 | 11.7 | 12.4 | 10.8 | 10.4 |
| Expenses | 11.3 | 7.5 | 5.9 | 12.2 | 15.3 | 10.9 | 11.5 | 9.4 | 9.3 |
| Operating Profit | 1.0 | 1.5 | 1.6 | 0.6 | 0.3 | 0.8 | 0.9 | 1.4 | 1.1 |
| OPM % | 7.87% | 16.24% | 21.35% | 4.92% | 2.23% | 7.12% | 7.01% | 12.9% | 10.4% |
| Other Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest | 0.5 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 |
| Depreciation | 0.3 | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.4 | 0.4 |
| Profit before tax | 0.1 | 0.6 | 0.8 | -0.3 | -0.5 | 0.0 | 0.1 | 0.5 | 0.1 |
| Tax % | 15.6% | -22.8% | -29.6% | -6.2% | -38.2% | -34.1% | -33.3% | -56.9% | 0% |
| Net Profit | 0.2 | 0.5 | 0.6 | -0.2 | -0.3 | 0.0 | 0.0 | 0.2 | 0.0 |
| EPS in Rs | 0.18 | 0.53 | 0.6 | -0.24 | -0.34 | 0.03 | 0.04 | 0.23 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -2% |
| 3 Years: | -6% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 0% |
| 3 Years: | 2% |
| TTM: | -108% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -7% |
| 5 Years: | 15% |
| 3 Years: | 6% |
| 1 Year: | -20% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | -104% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -7% |
| 5 Years: | 15% |
| 3 Years: | 6% |
| 1 Year: | -20% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|